ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0023

New Biomarkers in Hand Osteoarthritis: The Micro-RNA Signature

Maxime Auroux1, Marjorie Millet2, Blandine Merle2, Elisabeth Fontanges1, Florence Duvert1, Evelyne Gineyts3, Jean-Charles Rousseau3, Olivier Borel2, Alexandre Mercier1, Eric LESPESSAILLES4 and Roland Chapurlat1, 1Hospices Civils de Lyon, LYON, France, 2INSERM U1033, LYON, France, 3INSERM 1033, Lyon, France, 4Regional hospital centre of Orleans, France, ORLEANS, Centre, France

Meeting: ACR Convergence 2022

Keywords: Biomarkers, Epigenetics, hand, Micro-RNA, Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Osteoarthritis and Joint Biology – Basic Science Poster

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Hand osteoarthritis (HOA) is a highly prevalent disease, associated with important disability and socio-economic burden. Erosive HOA, almost exclusively found in women, induces more disability, but the pathophysiology is poorly known. Susceptibility genes identified to date only explain a minor proportion of the risk. We have hypothesized that epigenetic processes could play a role and we focused on micro-RNAs, which are small noncoding RNAs interfering with messenger RNAs, leading to their repression or destruction, as potential regulators involved in the pathophysiology of HOA.

Methods: We have assessed HOA status according to ACR criteria for HOA in 1189 post-menopausal women (the QUALYOR Study). We have studied the micro-RNA signature in two steps. First, in the screening phase, we have measured in blood samples the 768 most-described micro-RNAs using Taqman Low Density Array cards (TLDA) after RNA extraction, micro-RNAs reverse transcription and pre-amplification, in 3 different groups: 10 patients with erosive HOA (at least 3 erosive joints), 10 patients with symptomatic HOA without erosions and 10 controls without HOA matched for age and BMI. We have pairwise compared each micro-RNA expression level between HOA groups using Wilcoxon test. The p-values were corrected for false discovery rate (FDR) with the Benjamini-Hochberg method and were considered significant for values < 0.05. In a second step, we will proceed to the validation of micro-RNAs identified at screening phase in larger samples (60 patients with erosive HOA and 60 patients without HOA).

Results: We have first compared micro-RNAs expression levels between the erosive HOA group and controls. After exclusion of micro-RNAs weakly expressed and those that do not segregate clearly between groups, we have identified 12 down-regulated micro-RNAs and 4 up-regulated micro-RNAs. Among these, 4 down regulated (miR 373-3p, miR 558, miR 607 and miR 653-5p) and 3 up-regulated micro-RNAs (miR 142-3p, miR 144-3p and miR 34a-5p) were previously described in chondrocytes homeostasis or osteoarthritis. We have then compared micro-RNAs expression level between erosive HOA and non-erosive HOA but did not find any significant difference, possibly suggesting that even if these two HOA phenotypes are clinically different, some of the pathophysiological mechanisms might be shared.

Conclusion: We have identified for the first time in HOA a micro-RNA signature associated to the disease, that will be validated in the second step of the study. This micro-RNA signature could become a biomarker of interest and could help better understanding the pathophysiology.

Supporting image 1


Disclosures: M. Auroux, None; M. Millet, None; B. Merle, None; E. Fontanges, None; F. Duvert, None; E. Gineyts, None; J. Rousseau, None; O. Borel, None; A. Mercier, None; E. LESPESSAILLES, None; R. Chapurlat, None.

To cite this abstract in AMA style:

Auroux M, Millet M, Merle B, Fontanges E, Duvert F, Gineyts E, Rousseau J, Borel O, Mercier A, LESPESSAILLES E, Chapurlat R. New Biomarkers in Hand Osteoarthritis: The Micro-RNA Signature [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/new-biomarkers-in-hand-osteoarthritis-the-micro-rna-signature/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/new-biomarkers-in-hand-osteoarthritis-the-micro-rna-signature/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology